AFP and hepatocellular carcinoma: This approach was demonstrated in the REACH (NCT01140347) and REACH‐2 (NCT02435433) trials, where Ramucirumab (a monoclonal antibody targeting the VEGF2 receptor) was shown to have increased overall survival benefits in patients with advanced HCC who had elevated serum concentrations of α‐fetoprotein (AFP) (>400 ng/ml),62, 63 which ultimately led to its regulatory approval by the FDA for second‐line treatment of advanced HCC.42, 43, 45, 46, 47, 49